GlassScriptPhysician profile
Munjal Girish Shroff
NPI 1093862948
$316,322.40
in general payments reported to CMS, 2019-2025
44 companies · $35K in 2025
The $35K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $25K · 2021: $44K · 2022: $95K · 2023: $58K · 2024: $38K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Consulting Fee: $21K · Honoraria: $20K · Food and Beverage: $9,693 · Travel and Lodging: $3,940 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,675.00 |
| Consulting Fee | $20,800.00 |
| Honoraria | $19,650.00 |
| Food and Beverage | $9,692.63 |
| Travel and Lodging | $3,940.43 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $135,486.06 | 2021-2025 | Vraylar |
| Corium, LLC | $59,164.13 | 2021-2025 | Azstarys, Azstarys |
| Allergan, INC. | $45,426.00 | 2019-2021 | |
| Axsome Therapeutics, INC. | $39,821.34 | 2022-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $27,860.28 | 2021-2024 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $902.43 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $807.56 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Harmony Biosciences LLC | $653.08 | 2020-2025 | Wakix |
| Janssen Pharmaceuticals, INC | $594.69 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $550.82 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $528.72 | 2021-2025 | Caplyta |
| Lundbeck LLC | $483.10 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $471.80 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $455.27 | 2022-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $398.72 | 2019-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $374.68 | 2022-2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $247.76 | 2023-2025 | Xelstrym, Secuado |
| Indivior INC. | $244.51 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $243.11 | 2020-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Tris Pharma INC | $237.88 | 2022-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $237.36 | 2019-2025 | Wellbutrin, Aplenzin |
| Neos Therapeutics, LP | $161.29 | 2020-2025 | Adzenys Xr-Odt |
| Brainsway USA INC | $115.05 | 2019-2024 | Brainsway Deep Tms System |
| Idorsia Pharmaceuticals US INC | $99.68 | 2023-2024 | Quviviq |
| Inspire Medical Systems, INC. | $87.76 | 2023 | Inspire |
| Eisai INC. | $75.16 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $70.03 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $69.28 | 2021-2023 | Belsomra |
| Almatica Pharma LLC | $61.32 | 2024-2025 | Loreev Xr |
| Adlon Therapeutics L.P. | $57.62 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $46.43 | 2019-2024 | Relexxii |
| Luye Pharma (USA) LTD. | $44.50 | 2025 | Erzofri Extended-Release |
| Amgen INC. | $42.93 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $39.25 | 2025 | Lumryz |
| Sunovion Pharmaceuticals INC. | $21.84 | 2022 | |
| Avion Pharmaceuticals | $19.14 | 2023 | Methylphenidate Hydrochloride |
| Mdd US Operations, LLC | $17.54 | 2019 | |
| Alfasigma USA, INC. | $17.29 | 2021 | |
| Shire North American Group INC | $16.85 | 2019 | |
| Owp Pharmaceuticals, INC. | $16.29 | 2019 | |
| Amarin Pharma, INC. | $14.58 | 2019 | |
| Masimo Corporation | $14.02 | 2023 | Bridge |
| Aytu Biopharma, INC. | $13.20 | 2019 | |
| Orexo US, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munjal Shroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.